Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.

Oncotarget · 2016 · PMC5058727 · PMID 27127178

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

However, our data showed only a marginally significant decrease in KTC1-VEM2 cell growth and no significant difference in KTC1-VEM1 cell growth, when compared to KTC1-DMSO cells, in response to CRAF knockdown ( Supplementary Figure 4 ).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.